Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which … Read more
Telix Pharmaceuticals Limited (TLX) - Total Liabilities
Latest total liabilities as of December 2025: $1.15 Billion USD
Based on the latest financial reports, Telix Pharmaceuticals Limited (TLX) has total liabilities worth $1.15 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Telix Pharmaceuticals Limited - Total Liabilities Trend (2000–2025)
This chart illustrates how Telix Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Telix Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Telix Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alupar Investimento SA
SA:ALUP11
|
Brazil | R$19.12 Billion |
|
Acushnet Holdings Corp
NYSE:GOLF
|
USA | $1.50 Billion |
|
Kokuyo Co., Ltd.
PINK:KUKYF
|
USA | $85.57 Billion |
|
Mineral Res
PINK:MALRY
|
USA | $7.71 Billion |
|
Frasers Centrepoint Trust
PINK:FRZCF
|
USA | $2.23 Billion |
|
Digitalbridge Group Inc
NYSE:DBRG
|
USA | $968.96 Million |
|
Optowide Technologies Co. Ltd. A
SHG:688195
|
China | CN¥343.63 Million |
|
Operadora de Sites Mexicanos S.A. de C.V
PINK:OPMXF
|
USA | $56.45 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Telix Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Telix Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Telix Pharmaceuticals Limited (2000–2025)
The table below shows the annual total liabilities of Telix Pharmaceuticals Limited from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.15 Billion | +21.14% |
| 2024-12-31 | $948.22 Million | +280.21% |
| 2023-12-31 | $249.39 Million | +42.23% |
| 2022-12-31 | $175.35 Million | +65.15% |
| 2021-12-31 | $106.17 Million | +34.73% |
| 2020-12-31 | $78.81 Million | +147.22% |
| 2019-12-31 | $31.88 Million | +33.92% |
| 2018-12-31 | $23.80 Million | +1221.74% |
| 2017-12-31 | $1.80 Million | -91.16% |
| 2016-12-31 | $20.38 Million | +13.07% |
| 2015-12-31 | $18.03 Million | -9.44% |
| 2014-12-31 | $19.91 Million | +16.84% |
| 2013-12-31 | $17.04 Million | -26.68% |
| 2011-12-31 | $23.24 Million | +6501.41% |
| 2000-12-31 | $352.00K | -- |